Development of Novel Approaches for the Treatment of Cutaneous Candidiasis

The main culprit behind cutaneous candidiasis, a fungal infection that can lead to major dermatological and systemic health problems, is Candida albicans. Over the past 20 years, cutaneous candidiasis has become more prevalent, especially in hospitalized or immunocompromised patients. Conventional treatment methods employ antifungal drugs like azoles and polyenes, which are effective but have drawbacks because of their high recurrence rates, negative side effects, and growing antifungal resistance. This study highlights recent advancements in novel treatment techniques for cutaneous candidiasis. New antifungal medications that more precisely target specific fungal pathways, including echinocandins and triazole derivatives, are examples of emerging techniques. The most common symptoms are interdigital candidiasis, cheilitis, intertrigo, and diaper dermatitis, but they can occur elsewhere in the body. Other types of Candida may be the reason for infections that occur from person to person, even though C. Candida albicans is the most frequent culprit. The most typical signs of Candida infections are burning and tingling. Skin symptoms might vary, in any case. The two main signs of candidiasis are bright erythema and skin erosions with satellite pustules. Yeast is the main cause of cutaneous candidiasis. Candida, especially Candida albicans, is characterized by epidermal exposure of the skin, nails, interdigital space, and mucous membranes. This study discusses several species of C. parapsilosis, C. kefyr, C. krusei, C. glabrata, C. tropicalis, C. parapsilosis, C. guilliermondii, C. lusitaniae, and C. albicans. The primary targets of antifungal drugs are the nucleic acids, cell walls, and cell membranes of Candida species.